Search

Displaying results 1281 - 1290 of 10000 in total
  1. Drug

    Influenza A virus A/Brisbane/10/2010 (H1N1) hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB14398
    Approved

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Synonyms: Influenza A virus A/Brisbane/10/2010 (H1N1) hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)
  2. Drug

    Influenza B virus B/Hong Kong/259/2010 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB14435
    Approved

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

    Synonyms: Influenza B virus B/Hong Kong/259/2010 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)
  3. Drug

    Fremanezumab

    go.drugbank.com/drugs/DB14041
    ApprovedInvestigational

    [L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. … [L11779] Along with other recently approved anti-CGRP therapies such as [galcanezumab], [erenumab], and the oral CGRP antagonist [ubrogepant], fremanezumab represents an important step forward in the treatment

    Products: AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5ML, AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225 MG/1.5ML
  4. Drug

    Anakinra

    go.drugbank.com/drugs/DB00026
    ApprovedInvestigational

    On November 14, 2001, it was approved by the FDA for the treatment of rheumatoid arthritis. … It was later approved for the treatment of NOMID and DIRA on December 21, 2012, and December 18, 2020, respectively.

    Products: Kıneret 100 mg/ 0.67 ml Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Enjektör, 7 ADET, Kıneret 100 mg/ 0.67 ml Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Enjektör, 28 ADET
  5. Drug

    Pipotiazine

    go.drugbank.com/drugs/DB01621
    ApprovedInvestigationalWithdrawn

    Pipotiazine has actions similar to those of other phenothiazines. Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depr...

    Products: PIPORTIL ® L-4SOLUCION INYECTABLE AL 2.5% (100 MG)., TRIPIPOT® SOLUCIÓN INYECTABLE 25 MG/ML
  6. Drug

    Galcanezumab

    go.drugbank.com/drugs/DB14042
    ApprovedInvestigational

    [L42060] It is unknown if galcanezumab has an effect on pregnancy outcomes. A pregnancy exposure registry has been established to evaluate the safety of this drug in pregnant women.[L42060] … [A33112] Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive treatment of migraine and the treatment of episodic cluster headache.

    Products: EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100 MG/ML, EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED PEN 120 MG/ML
  7. Drug

    Enflurane

    go.drugbank.com/drugs/DB00228
    ApprovedVet approvedWithdrawn

    In addition, it is known to cause increased cardio depressant effects when compared to other inhaled anesthetics.[A202022] … Enflurane is a halogenated inhalational anesthetic initially approved by the FDA in 1972. Since this date, it has been withdrawn from the US market.

    Products: ENFLURANE USP INHALASYON İÇİN SOLÜSYON, 250 ML
  8. Drug

    Oxiconazole

    go.drugbank.com/drugs/DB00239
    Approved

    Oxiconazole is an antifungal agent that is commonly found in topical formulations. … It is marketed under the brand names Oxistat and Oxistat, and is used in the treatment of various skin infections such as athlete's foot, jock itch and ringworm.

    Products: OXEZOLE %1 KREM, 20 G, OXEZOLE %1 DERI SPREYI, ÇÖZELTİ 20 ML
  9. Drug

    Rituximab

    go.drugbank.com/drugs/DB00073
    ApprovedInvestigational

    FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) [L4811], however, has now been approved for a variety of conditions [FDA label]. … On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808].

    Categories: CD20 (Clusters of Differentiation 20) inhibitorsProducts: MABTHERA ® CONCENTRADO DE SOLUCIÓN PARA INFUSIÓN 500 MG / 50 ML, MABTHERA CONCENTRATE FOR SOLUTION FOR INFUSION 500 mg/50ml
  10. Drug

    Busulfan

    go.drugbank.com/drugs/DB01008
    ApprovedInvestigational

    It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. … According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.

    Products: MYLERAN 2 MG TABLET, 100 ADET, MYRAN TABLETS 2 mg